- Product
- ‘Disclose the pricing rationale used for COVID-19 drugs'
- by Kang, Hye-Kyung Oct 2, 2024 05:49am
- The Korean Pharmacists for Democratic Society (CEO Kyungrim Jeon, KPDS) has called for the disclosure of the cost-effectiveness evaluation results of the COVID-19 treatments Paxlovid and Veklury Inj. “The Ministry of Health and Welfare is engaging in the atrocity of setting excessive drug prices for COVID-19 treatments,” said the KPDS o
- Product
- Zomig distributor changes from AZ to SK Chemicals
- by Kim JiEun Sep 25, 2024 05:49am
- The distributor of Zomig Tab, a triptan used in the treatment of migraine, will change from AstraZeneca Korea to SK Chemical. The distribution industry suggests that the change in a distributor could impact the supply and demand chain. AstraZeneca Korea recently sent an official letter to the pharmaceutical wholesaler community of 'termina
- Product
- Concerns arise about securing COVID-19 treatment shortages
- by Kang, Hye-Kyung Aug 14, 2024 05:51am
- COVID-19 is spreading due to the circulating KP.3 variant. We have not learned lessons from the previous spread of the Omicron variant. As demand for test kits surges, there are no remaining stocks at online pharmacies. Even test kits with an expiration date within the end of October are no longer available. Due to shortages of oral medicine
- Product
- 92 patient groups implore doctors to stop the strike
- by Kang Hye-Kyung Jun 14, 2024 05:46am
- “We strongly demand the doctors withdraw their resolutions to take a collective leave of absence and indefinite leave of absence as they threaten the patients' lives and health." Ninety-two patient advocacy organizations have called for the withdrawal of the medical community's collective strike that is set to start on the 18th. Ninet
- Product
- Selection dilemma rises in IBD mkt due to increased options
- by Moon, sung-ho Jun 11, 2024 05:48am
- With the recent surge in treatment options for inflammatory bowel disease (IBD), which is represented by ulcerative colitis and Crohn's disease, developing an appropriate treatment strategy for IBD is emerging as a rising topic in clinical practice. This is due to the recent health insurance reimbursement extensions granted for treatments by
- Product
- Will Osimertinib emerge as the standard of care
- by Park, sang-jun Jun 10, 2024 05:41am
- The LAURA trial, which evaluated osimertinib’s effect in patients with unresectable Stage III EGFR-mutant non-small cell lung cancer who received chemoradiotherapy (CRT), was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also concurrently published in NEJM. The LAURA trial evaluated
- Product
- The Court rejects petitions on drug pricing negotiations
- by Kang, Shin-Kook May 3, 2024 05:53am
- The Constitutional Court of Korea (hereafter referred to as the Constitutional Court) made a decision to reject pharmaceutical company’s petition, which alleged a constitutional violation related to the drug pricing negotiations order. The Constitutional Court recently announced that the clause of a claim, including the violation of th
- Product
- Will Prolia be able to continue on its high growth in KOR?
- by Moon, sung-ho Apr 24, 2024 05:45am
- The government will extend reimbursement for osteoporosis drugs, including Prolia (denosumab, Amgen). In particular, along with the reimbursement extension, the government has allowed switching between osteoporosis drugs. According to industry sources on the 20th, the Ministry of Health and Welfare recently issued an administrative notice of
- Product
- ‘Wholesale inventory of 110 antitumor drugs at its lowest'
- by Kang, Hye-Kyung Apr 12, 2024 05:41am
- The Korean Pharmacists for Democratic Society (President: Kyung-Lim Jeon, KPDS) has pointed out the issue of antineoplastic drugs being out of stock. In the second week of April, the KPDS revealed through the ‘Stock Shortage Drugs of the Week Report’ that an estimated wholesale stock of 110 antineoplastic drugs has run out. The 110 ite
- Product
- KPA, “to discuss ingredient prescribing in upcoming FAPA"
- by Kim JiEun Mar 5, 2024 05:49am
- Kwang-Hoon Choi, President of the Korean Pharmaceutical Association (KPA), has announced that he would assign the proposal for active ingredient prescribing as the priority agenda for the Federation of Asian Pharmaceutical Associations (FAPA) Congress, which is scheduled to be held in October this year. Choi aims to convince the Korean citi
